MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX)

Q: What does CUSIP 61559X104 represent in this 13F holders report?

CUSIP 61559X104 is the security identifier for MLTX - MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held MLTX - MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share in Q4 2022?

32 institutional investors reported MLTX - MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share for Q4 2022. Use the holders table for investor-level position and value details.

CUSIP: 61559X104

Q4 2022 13F Holders as of 31 Dec 2022

Security type / class: Equity / Class A ordinary share, par value $0.0001 per share
Total 13F shares: 37,748,780
Total 13F value: $396,358,589
Share change: +563,294
SEC-reported price per share: $10.50
Number of holders: 32
Value change: +$8,234,061
Number of buys: 17
Number of sells: 11
Shares outstanding: 81,224,792

Security key

61559X104

Report period

Q4 2022

Institutions

Top holders

MLTX full security history Ownership snapshot Full 13F holder table MoonLake Immunotherapeutics SEC filings MoonLake Immunotherapeutics company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of MLTX - MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

BVF INC/IL

Disclosed value leader

BVF INC/IL

Comparable rows

15/15

Latest evidence

30 Sep 2022

13F Lead comparable stake: 27% Showing 1-6 of 15 holder rows.

Quick read

BVF INC/IL leads the comparable SEC ownership view at 27%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BVF INC/IL's linked filing trail.

Comparable ownership Top 5

BVF INC/IL 27%

Cormorant Asset Management, LP 7.5%

CITADEL ADVISORS LLC 3.3%

TCG Crossover Management, LLC 1.2%

PRICE T ROWE ASSOCIATES INC /MD/ 1.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
BVF INC/IL	13F Company 13F	27%	$173,140,000 21,751,284 shares	—	30 Sep 2022
Cormorant Asset Management, LP	13F Company 13F	7.5%	$47,064,000 6,065,001 shares	—	30 Sep 2022
CITADEL ADVISORS LLC	13F Company 13F	3.3%	$21,380,000 2,685,937 shares	—	30 Sep 2022
TCG Crossover Management, LLC	13F Company 13F	1.2%	$7,760,000 1,000,000 shares	—	30 Sep 2022
PRICE T ROWE ASSOCIATES INC /MD/	13F Company 13F	1.1%	$6,921,000 869,388 shares	—	30 Sep 2022
FMR LLC	13F Company 13F	1%	$6,521,000 819,177 shares	—	30 Sep 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

37,748,780

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders

Q4 2022 holders

Holder diff

Investor	Q3 2022 Shares	Q4 2022 Shares	Share Diff	Share Chg %	Q3 2022 value	Q4 2022 value	Value change	Value Chg %